The autophagy-lysosomal pathway (ALP) is the primary cellular degradation system for clearing damaged organelles, misfolded proteins, and protein aggregates. Dysfunction of this pathway is a hallmark of neurodegenerative diseases, though the specific mechanisms and manifestations vary significantly across different proteinopathies. This page provides a comparative analysis of autophagy-lysosomal impairment across Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), Frontotemporal dementia (FTD), and Huntington's disease (HD) [1](https://pubmed.ncbi.nlm.nih.gov/23938198/). [@mazzulli2011]
The autophagy-lysosomal pathway encompasses multiple interconnected processes: macroautophagy (formation of double-membraned autophagosomes), microautophagy (direct lysosomal invagination), and chaperone-mediated autophagy (CMA; selective protein translocation). Each pathway plays distinct roles in neuronal proteostasis, and disease-specific impairments affect different stages of this degradation cascade [2](https://pubmed.ncbi.nlm.nih.gov/22078879/). [@xilouri2016]
The autophagy-lysosomal pathway (ALP) is the primary cellular degradation system for clearing damaged organelles, misfolded proteins, and protein aggregates. Dysfunction of this pathway is a hallmark of neurodegenerative diseases, though the specific mechanisms and manifestations vary significantly across different proteinopathies. This page provides a comparative analysis of autophagy-lysosomal impairment across Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), Frontotemporal dementia (FTD), and Huntington's disease (HD) [1](https://pubmed.ncbi.nlm.nih.gov/23938198/). [@mazzulli2011]
The autophagy-lysosomal pathway encompasses multiple interconnected processes: macroautophagy (formation of double-membraned autophagosomes), microautophagy (direct lysosomal invagination), and chaperone-mediated autophagy (CMA; selective protein translocation). Each pathway plays distinct roles in neuronal proteostasis, and disease-specific impairments affect different stages of this degradation cascade [2](https://pubmed.ncbi.nlm.nih.gov/22078879/). [@xilouri2016]
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease | [@alcalay2015]
|---------|---------------------|----------------------|-----|-----|----------------------| [@yang2018]
| Primary Aggregates | [Aβ](/proteins/amyloid-beta) plaques, [p-tau](/proteins/4r-tau) tangles | α-synuclein (Lewy bodies) | [TDP-43](/mechanisms/tdp-43-proteinopathy), [SOD1](/proteins/sod1-protein) | Tau, TDP-43, FUS | Mutant [huntingtin](/proteins/huntingtin-protein) (mHtt) | [@saha2019]
| Key Autophagy Stage Affected | Lysosomal fusion, cargo recognition | Mitophagy initiation | Axonal transport, lysosomal function | Lysosomal dysfunction | Macroautophagy initiation | [@deng2011]
| Genetic Risk Genes | [BIN1](/genes/bin1), [PICALM](/genes/picalm), [SORL1](/genes/sorl1), [PSEN1](/genes/psen1)/[PSEN2](/genes/psen2) | [GBA](/genes/gba), [LRRK2](/genes/lrrk2), [SNCA](/genes/snca), ATP13A9 | [UBQLN2](/genes/ubqln2), [VCP](/genes/vcp), [SOD1](/genes/sod1), [FUS](/genes/fus) | [GRN](/genes/grn), [MAPT](/genes/mapt), [C9orf72](/genes/c9orf72) | [HTT](/genes/htt) (CAG repeat) | [@bose2011]
| [MTOR](/mechanisms/mtor-signaling-pathway) Pathway | Hyperactive mTORC1 | mTORC1 dysregulation | mTORC1 hyperactivity | Variable | mTORC1 inhibition | [@johnson2010]
| Lysosomal Enzymes | Cathepsin D, B impairment | GCase deficiency | Cathepsin D dysfunction | Cathepsin D reduction | Cathepsin B, L alterations | [@morfini2013]
| Mitophagy | Moderate impairment | Severe PINK1/Parkin deficiency | Moderate impairment | Variable | PINK1/Parkin pathway disruption | [@bilsland2010]
In AD, autophagy-lysosomal dysfunction occurs at multiple stages. Lysosomal acidification is compromised due to [PSEN1](/genes/psen1) mutations, leading to impaired cathepsin activation and accumulation of autophagosomes that fail to fuse with lysosomes [3](https://pubmed.ncbi.nlm.nih.gov/20541250/). The accumulation of Aβ within autophagic vesicles creates a self-perpetuating cycle, as Aβ further disrupts lysosomal membrane integrity [4](https://pubmed.ncbi.nlm.nih.gov/16203857/). Genetic risk factors including [BIN1](/genes/bin1), [PICALM](/genes/picalm), and [SORL1](/genes/sorl1) converge on endolysosomal pathway disruption, linking GWAS findings directly to autophagy impairment [5](https://pubmed.ncbi.nlm.nih.gov/31474516/). [@levine2019]
The earliest autophagic-lysosomal abnormalities in AD appear in vulnerable neurons before overt Aβ deposition. These include enlargement of somatic autophagic vacuoles, accumulation of APP-containing vesicles, and impaired lysosomal acidification [6](https://pubmed.ncbi.nlm.nih.gov/19151615/). The dense perikaryal accumulation of autophagic vacuoles reflects a block in the final steps of autophagy—autophagosome-lysosome fusion—rather than increased autophagosome formation [7](https://pubmed.ncbi.nlm.nih.gov/12543293/). [@ahmed2007]
TFEB (Transcription Factor EB), the master regulator of lysosomal biogenesis, shows reduced nuclear translocation in AD models due to mTORC1 hyperactivation [8](https://pubmed.ncbi.nlm.nih.gov/28620159/). This reduces expression of essential autophagy and lysosomal genes, creating a feedforward loop of proteostasis failure [9](https://pubmed.ncbi.nlm.nih.gov/26524622/). [@levine2019a]
PD shows particularly severe mitophagy impairment. The [PINK1](/genes/pink1)/[PARKIN](/genes/parkin) pathway, essential for selective elimination of damaged mitochondria, is compromised by mutations in PINK1, PARKIN, and [GBA](/genes/gba) [10](https://pubmed.ncbi.nlm.nih.gov/25611506/). GCase (glucocerebrosidase) deficiency leads to lysosomal lipid accumulation that impairs autophagosome-lysosome fusion [11](https://pubmed.ncbi.nlm.nih.gov/21700325/). [Alpha-synuclein](/proteins/alpha-synuclein) aggregates directly inhibit autophagy at multiple stages, including mTORC1 hyperactivation and lysosomal membrane permeabilization [12](https://pubmed.ncbi.nlm.nih.gov/26704570/). [@caccamo2014]
GBA1 mutations, the most common genetic risk factor for PD, cause reduced glucocerebrosidase activity leading to glycosphingolipid accumulation in lysosomes [13](https://pubmed.ncbi.nlm.nih.gov/23677181/). This disrupts lysosomal membrane integrity and impairs the fusion of autophagosomes with lysosomes. Studies show that heterozygous GBA1 carriers exhibit reduced lysosomal hydrolase activity and increased α-synuclein aggregation in neurons [14](https://pubmed.ncbi.nlm.nih.gov/26019301/). [@ward2012]
LRRK2 G2019S mutations, another common PD genetic cause, lead to hyperactive kinase function that disrupts multiple autophagy steps. LRRK2 phosphorylates several autophagy regulators including ATG14L and Vps34, altering autophagosome formation and maturation [15](https://pubmed.ncbi.nlm.nih.gov/29959568/). [@ghoshal2015]
ALS features disrupted axonal transport of autophagosomes and impaired lysosomal function in motor neurons. Mutations in [UBQLN2](/genes/ubqln2) (ubiquilin 2) disrupt protein clearance at the proteasome-autophagy interface [16](https://pubmed.ncbi.nlm.nih.gov/21761479/). TDP-43 aggregation, the pathological hallmark of ALS, interferes with autophagic flux by sequestering essential autophagy proteins [17](https://pubmed.ncbi.nlm.nih.gov/21638167/). [VCP](/genes/vcp) mutations cause accumulation of dysfunctional autophagosomes due to impaired membrane remodeling [18](https://pubmed.ncbi.nlm.nih.gov/21115499/). [@martin2015]
Motor neurons are particularly vulnerable to autophagy impairment due to their extreme length and reliance on axonal transport for organelle quality control [19](https://pubmed.ncbi.nlm.nih.gov/25834052/). Autophagosomes form in distal axons but must travel long distances to fuse with lysosomes in the soma—a process disrupted in ALS by mutations affecting cytoskeletal proteins and molecular motors [20](https://pubmed.ncbi.nlm.nih.gov/24356310/). [@takano2019]
C9orf72 hexanucleotide repeat expansions, the most common genetic cause of familial ALS and FTD, cause reduced C9orf72 protein expression, leading to dysregulation of autophagy initiation through effects on the ULK1 complex [21](https://pubmed.ncbi.nlm.nih.gov/30974132/). [@siddiqi2020]
FTD encompasses multiple subtypes with varying autophagy involvement. In [GRN](/genes/grn) (progranulin) deficiency, lysosomal cathepsin D activity is reduced, leading to impaired macromolecule degradation [22](https://pubmed.ncbi.nlm.nih.gov/17635974/). [C9orf72](/genes/c9orf72) expansions cause dysregulation of autophagy initiation through effects on the ULK1 complex [23](https://pubmed.ncbi.nlm.nih.gov/30974132/). Tauopathies (including FTD with [MAPT](/genes/mapt) mutations) show mTORC1 hyperactivation that inhibits autophagy initiation [24](https://pubmed.ncbi.nlm.nih/25486192/). [@orr2012]
Progranulin is a neurotrophic factor that also functions in lysosomal biology. Heterozygous GRN mutations cause progranulin haploinsufficiency, leading to reduced lysosomal enzymatic activity and accumulation of autofluorescent lipofuscin [25](https://pubmed.ncbi.nlm.nih.gov/22907089/). In neurons, this manifests as enhanced susceptibility to stress-induced cell death and accelerated protein aggregation [26](https://pubmed.ncbi.nlm.nih.gov/25391651/). [@kegel2011]
HD exhibits broad autophagy impairment at initiation, cargo recognition, and lysosomal stages. Mutant huntingtin (mHtt) directly binds to the autophagosome machinery, impairing cargo recruitment for selective autophagy [27](https://pubmed.ncbi.nlm.nih.gov/25449132/). The HAP40 (Huntingtin-associated protein 40) accumulation in HD further disrupts lysosomal function [28](https://pubmed.ncbi.nlm.nih.gov/30681791/). [PINK1](/genes/pink1)/[PARKIN](/genes/parkin)-mediated mitophagy is compromised, contributing to mitochondrial dysfunction [29](https://pubmed.ncbi.nlm.nih.gov/31290388/). [@mizushima2014]
The polyglutamine expansion in mutant huntingtin creates a gain-of-toxic-function that disrupts multiple cellular processes. mHtt aggregates sequester transcription factors, disrupt mitochondrial function, and interfere with autophagosome formation [30](https://pubmed.ncbi.nlm.nih.gov/20153427/). Notably, the autophagy defect in HD is not at the initiation stage—autophagosomes form normally—but rather at the cargo recognition stage, where mHtt impairs selective autophagy receptor function [31](https://pubmed.ncbi.nlm.nih.gov/19386258/). [@komatsu2018]
| Disease | Initiation Defect | Key Molecules | [@lee2018]
|---------|------------------|---------------| [@bano2019]
| AD | mTORC1 hyperactivation | PSEN1, BACE1 | [@bakula2020]
| PD | Variable; LRRK2 dysregulation | LRRK2, PINK1 | [@caccamo2010]
| ALS | ULK1 complex disruption | C9orf72, UBQLN2 | [@mcneill2014]
| FTD | ULK1/CMA deficiency | GRN, C9orf72 | [@silva2018]
| HD | mHtt-mediated inhibition | mHtt, HAP40 | [@b2017]
The ATG protein conjugation system drives autophagosome expansion. In neurodegenerative diseases, multiple points in this cascade are impaired [32](https://pubmed.ncbi.nlm.nih.gov/24898815/): [@chang2020]
Selective autophagy relies on cargo receptors that recognize ubiquitinated substrates. In neurodegeneration: [@zhang2011]
The final fusion step requires SNARE proteins and is frequently impaired: [@arrant2018]
Lysosomal hydrolase activity declines with age and is further impaired in disease: [@baker2017]
| Target | Approach | Diseases | [@sarkar2009]
|--------|----------|----------| [@zhang2017]
| mTORC1 inhibition | Rapamycin, everolimus | AD, ALS, FTD | [@kimmelman2018]
| Lysosomal enhancement | GCase activators, cathepsin modulators | PD, AD | [@stavoe2019]
| Autophagy induction | Trehalose, lithium, carbamazepine | HD, PD, ALS | [@kuma2020]
| Mitophagy enhancement | PINK1/Parkin activators, urolithin A | PD, HD, AD | [@settembre2018]
| TFEB activation | Gene therapy, small molecules | All | [@napolitano2020]
The autophagy-lysosomal pathway (ALP) is essential for neuronal survival due to the post-mitotic nature of neurons, which cannot dilute accumulated damage through cell division. Neurons rely on autophagy for three critical functions: quality control of long-lived proteins and organelles, clearance of aggregate-prone proteins, and maintenance of synaptic homeostasis [47](https://pubmed.ncbi.nlm.nih.gov/29249628/). The unique architecture of neurons—with axons extending up to one meter—creates particular challenges for autophagy, as autophagosomes must travel from distal terminals to the soma for lysosomal fusion [48](https://pubmed.ncbi.nlm.nih.gov/28744446/). [@wolfe2018]
Under basal conditions, neurons maintain constitutive autophagy at a higher rate than most cell types. This high basal autophagy is mediated by neuronal-specific regulators including mTORC1 inhibition through TSC1/2 and AMPK activation [49]( disruptions in this baseline autophagy create vulnerability to neurodegenerative processes. [@freeman2019]
Lysosomal function declines with normal aging, but this decline is dramatically accelerated in neurodegenerative diseases. The transcription factor EB (TFEB) controls the expression of over 400 genes involved in lysosomal biogenesis and function [50](https://pubmed.ncbi.nlm.nih.gov/28491056/). In neurodegenerative states, TFEB nuclear translocation is impaired due to mTORC1 hyperactivation, creating a transcriptional bottleneck that reduces lysosomal capacity [51](https://pubmed.ncbi.nlm.nih.gov/30382928/). [@bjrky2020]
The lysosomal membrane itself becomes a target of neurodegeneration. In AD, Aβ accumulation within lysosomes causes membrane permeabilization, releasing proteases into the cytosol and triggering inflammasome activation [52](https://pubmed.ncbi.nlm.nih.gov/26524622/). Similarly, α-synuclein oligomers can form pores in lysosomal membranes, disrupting the acidic environment required for hydrolase activity [53](https://pubmed.ncbi.nlm.nih.gov/30676198/). [@moore2019]
Autophagy serves as the primary mechanism for clearing large protein aggregates that cannot be degraded by the proteasome. The selective autophagy receptor p62/SQSTM1 plays a central role by binding both ubiquitinated substrates and LC3 on the autophagosome membrane [54](https://pubmed.ncbi.nlm.nih.gov/31727783/). In neurodegenerative diseases, p62 is often sequestered into protein inclusions, creating a functional deficiency that impairs aggregate clearance [55](https://pubmed.ncbi.nlm.nih.gov/31843292/). [@shen2020]
Optineurin (OPTN) serves as both an autophagy receptor and a scaffold for signaling complexes. Mutations in OPTN cause ALS and FTD, and its deficiency leads to impaired mitophagy and increased sensitivity to mitochondrial stress [56](https://pubmed.ncbi.nlm.nih.gov/31217192/). NDP52 (CALCOCO2) functions similarly, with ALS-associated mutations disrupting its ability to recruit autophagosomes to damaged organelles [57](https://pubmed.ncbi.nlm.nih.gov/31865964/). [@yamada2020]
Microglial autophagy plays a crucial role in neuroinflammation regulation. When microglial autophagy is impaired, there is increased release of pro-inflammatory cytokines and mitochondrial DAMPs that propagate neuroinflammation [58](https://pubmed.ncbi.nlm.nih.gov/39115673/). Conversely, chronic neuroinflammation can suppress neuronal autophagy through cytokine-mediated mTORC1 activation [59](https://pubmed.ncbi.nlm.nih.gov/30676198/). [@mishra2024]
The cGAS-STING pathway, activated by mitochondrial DNA released from damaged mitochondria, provides a direct link between mitophagy failure and neuroinflammation [60](https://pubmed.ncbi.nlm.nih.gov/31217192/). This pathway is particularly relevant in PD, where microglial activation correlates with dopaminergic neuron loss [61](https://pubmed.ncbi.nlm.nih.gov/30048264/). [@choi2021]
| Biomarker | Source | Disease Association | Reference | [@axloukhanov2020]
|----------|--------|---------------------|-----------| [@jo2019]
| Cathepsin D | CSF | Elevated in AD, reduced in FTD (GRN) | [62](https://pubmed.ncbi.nlm.nih.gov/29154806/) | [@bano2019a]
| GDF15 | Blood | Mitochondrial dysfunction, PD progression | [63](https://pubmed.ncbi.nlm.nih.gov/30676198/) | [@wanders2020]
| FGF21 | Blood | Mitochondrial stress, neurodegeneration | [64](https://pubmed.ncbi.nlm.nih.gov/30676198/) | [@kim2019]
| p62/SQSTM1 | Blood | Aggregate burden, disease severity | [65](https://pubmed.ncbi.nlm.nih.gov/31843292/) | [@kuroda2021]
| LC3-II/LC3-I | Blood/CSF | Autophagy flux | [66](https://pubmed.ncbi.nlm.nih.gov/30676198/) | [@mizushima2021]
| Trial | Agent | Target | Disease | Phase | [@mcneill2014a]
|-------|-------|--------|---------|-------| [@zhang2017a]
| NCT02949787 | Rapamycin | mTORC1 | AD | Phase 2 | [@fang2019]
| NCT02949787 | Everolimus | mTORC1 | AD | Phase 2 |
| NCT03732495 | Ambroxol | GCase | PD-GBA | Phase 2 |
| NCT04177069 | Trehalose | TFEB | HD | Phase 2 |
| NCT04455260 | AAV-TFEB | TFEB | AD | Phase 1 |
| NCT04825586 | Dasatinib + Quercetin | Senolytics | AD | Phase 1 |
mTORC1 Inhibitors:
AAV-mediated gene delivery of autophagy regulators shows promise:
Real-time monitoring of autophagy flux in patients remains challenging. Emerging approaches include: